| Literature DB >> 23117436 |
José Carlos Pelielo De Mattos1, Vanessa Coutinho de Matos, Michelle Pinheiro Rodrigues, Marcia Betânia Nunes de Oliveira, Flavio José S Dantas, Sebastião David Santos-Filho, Mario Bernardo-Filho, Adriano Caldeira-de-Araujo.
Abstract
Radiopharmaceuticals are employed in patient diagnostics and disease treatments. Concerning the diagnosis aspect, technetium-99m (99mTc) is utilized to label radiopharmaceuticals for single photon computed emission tomography (SPECT) due to its physical and chemical characteristics. 99mTc fixation on pharmaceuticals depends on a reducing agent, stannous chloride (SnCl(2)) being the most widely-utilized. The genotoxic, clastogenic and anegenic properties of the 99mTc-MDP(methylene diphosphonate used for bone SPECT) and SnCl(2) were evaluated in Wistar rat blood cells using the Comet assay and micronucleus test. The experimental approach was to endovenously administer NaCl 0.9% (negative control), cyclophosphamide 50 mg/kg b.w. (positive control), SnCl(2) 500 μg/mL or 99mTc-MDP to animals and blood samples taken immediately before the injection, 3, and 24 h after (in the Comet assay) and 36 h after, for micronucleus test. The data showed that both SnCl(2) and 99mTc-MDP-induced deoxyribonucleic acid (DNA) strand breaks in rat total blood cells, suggesting genotoxic potential. The 99mTc-MDP was not able to induce a significant DNA strand breaks increase in in vivo assays. Taken together, the data presented here points to the formation of a complex between SnCl(2) in the radiopharmaceutical 99mTc-MDP, responsible for the decrease in cell damage, compared to both isolated chemical agents. These findings are important for the practice of nuclear medicine.Entities:
Mesh:
Substances:
Year: 2012 PMID: 23117436 PMCID: PMC6268462 DOI: 10.3390/molecules171112974
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Comet assay of total blood cells of Wistar rats treated with NaCl 0.9% (Control); SnCl2 500 µg/mL and 99mTc-MDP. Blood was collected immediately before intravenous injections and in time intervals of 3 and 24 h after chemical solution administration. Results for each procedure comprise means from three experiments; error bars represent standard error mean. Different letters (a,b) correspond to significant (p < 0.05) statistical differences.
Micronucleus Test in Wistar rats bone marrow.
| Treatments | No. of Animals | Individual data a | N | % | Mean ± SD |
|---|---|---|---|---|---|
| NaCl 0.9% | 5 | 1.2, 2.0, 1.3, 1.2, 2.1 | 15 | 0.15 | 1.50 b ± 0.85 |
| Cyclophosphamide 50 mg/kg b.w. | 5 | 18.15, 22.13, 15.17, 20.12, 16.14 | 162 | 1.62 | 16.20 ± 3.12 |
| SnCl2 500 μg/mL | 5 | 2.1, 1.3, 2.3, 2.2, 3.3 | 22 | 0.22 | 2.20 b,c ± 0.79 |
| 99mTc-MDP 100 μCi | 5 | 1.2, 2.1, 2.3, 2.2, 2.1 | 18 | 0.18 | 1.80 b,c ± 0.63 |
a Per 1,000 polychromatic erythrocytes per rat; b Statistically different from the positive control (cyclophosphamide 50 mg/kg b.w.). * p < 0.05; c Not statistically different from the negative control (NaCl 0.9%); * p > 0.05.